Immunome Partnership
Undisclosed
UndisclosedPartnered
Key Facts
About Infinimmune
Infinimmune is a private, preclinical-stage biotech leveraging a proprietary platform to discover and engineer human-derived antibodies. The company's approach centers on sequencing millions of paired antibody sequences from human B cells, using its Anthrobody library-on-B-cell platform and AI-driven GLIMPSE model to rapidly identify and optimize candidates. With a pipeline focused on immunology and inflammation, including a lead IL-22 inhibitor for atopic dermatitis in CMC stage, Infinimmune aims to translate natural human immune responses into novel biologics with superior safety and efficacy profiles.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |